Apotex Inc. v. UCB, Inc.
Ferring B.V. v. Watson Labs, Inc.

AbbVie Inc. v. Kennedy Inst. of Rheumatology Trust

The Mathilda and Terrance Kennedy Institute of Rheumatology Trust (Kennedy) owns U.S. Patent Nos. 7,846,442 (the ’442 patent) and 6,270,766 (the ’766 patent). Both patents are directed towards methods of treating rheumatoid arthritis by co-administering two drugs. AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie) are licensees of the ’766 patent but not the ’442 patent. In 2011, AbbVie sued Kennedy in the Southern District of New York for a declaratory judgment that the ’442 patent was invalid under the doctrine of obviousness- type double patenting because the ’442 patent was not patentably distinct from the ’766 patent. We agree with AbbVie that the ’442 patent would have been obvious in light of the ’766 patent. Accordingly, we affirm the district court’s finding of invalidity.

Download AbbVie Inc. v. Kennedy Inst. of Rheumatology Trust

Registering your trademarks is one of the best long-term investments you can make in your business. Contact us today for more information.

Visit Gehrke & Associates, SC.


Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.


Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)